Li Xiaoye, Jin Qinchun, Yao Yao, Zhang Xiaochun, Lv Qianzhou
Department of Pharmacy, Zhongshan Hospital, Fudan University, 200032 Shanghai, China.
Department of Cardiology, Zhongshan Hospital, Fudan University, 200032 Shanghai, China.
Rev Cardiovasc Med. 2023 Nov 27;24(11):335. doi: 10.31083/j.rcm2411335. eCollection 2023 Nov.
Device-related thrombosis (DRT) after successful closure implantation on left atrial appendage (LAA) was considered as a major challenge and optimal strategy on antithrombotic therapy remains to be solved. This study was performed to compare the clinical effectiveness and safety of reduced rivaroxaban dose (RRD) and dual antiplatelet therapy (DAPT) after left atrial appendage closure (LAAC) implantation with the Watchman device.
After successful LAAC, consecutive participants were medicated with a standard DAPT or RRD. The primary endpoints included DRT, thrombosis events (TE), and bleeding events that were documented during a 12-month follow-up period.
767 patients (DAPT: n = 140; RRD: n = 627) were initially included. After propensity score matching (PSM), 140 patients treated with DAPT and 280 patients with RRD were included in each group with similar baseline information, thromboembolic and bleeding risk factors, cardiovascular risk factors and concomitant medication. In the RRD group, 193 patients were on rivaroxaban 15 mg ( ) and 47 received rivaroxaban 10 mg ( ). The incidence of DRT was documented in 12 (9.3%) patients in the DAPT group and 3 (6.3%) in and 7 (3.0%) in (log-rank = 0.050). DAPT subgroups were more likely to experience shorter time to DRT as compared to ( . DAPT hazard ratio (HR) = 0.334, = 0.015, 95% CI: 0.131-0.850). The median length of DRT in the group was significantly lower than that of the DAPT group (1.721 [1.610-1.818] mm . 1.820 [1.725-1.925] mm, = 0.029). Compared with the unadjusted estimated rates of ischemic events for patients with similar congestive heart failure, hypertension, age 75 years, diabetes mellitus, prior stroke or transient ischemic attack or thromboembolism, vascular disease, age 65-74 years, sex category ( - ) scores, a significant decrease of 68.6% in ischemic stroke rates was noted in the group, which contributed to a 54.9% reduction of overall thromboembolic events. The overall minor bleeding was not significantly different amongst the three groups ( = 0.944). Procedural bleeding was more common in the DAPT group, as compared with the and groups.
After successful closure implantation, long-term RRD significantly reduced the DRT and TE occurrence compared with DAPT.
左心耳(LAA)封堵植入成功后的器械相关血栓形成(DRT)被认为是一项重大挑战,抗栓治疗的最佳策略仍有待解决。本研究旨在比较使用Watchman装置进行左心耳封堵(LAAC)植入后,利伐沙班剂量降低(RRD)与双联抗血小板治疗(DAPT)的临床有效性和安全性。
LAAC成功后,连续纳入的参与者接受标准DAPT或RRD治疗。主要终点包括12个月随访期内记录的DRT、血栓形成事件(TE)和出血事件。
最初纳入767例患者(DAPT组:n = 140;RRD组:n = 627)。经过倾向评分匹配(PSM)后,每组纳入140例接受DAPT治疗的患者和280例接受RRD治疗的患者,两组患者的基线信息、血栓栓塞和出血风险因素、心血管风险因素及合并用药情况相似。在RRD组中,193例患者服用利伐沙班15 mg( ),47例患者服用利伐沙班10 mg( )。DAPT组有12例(9.3%)患者发生DRT,服用利伐沙班15 mg组有3例(6.3%),服用利伐沙班10 mg组有7例(3.0%)(对数秩 = 0.050)。与服用利伐沙班15 mg组相比,DAPT亚组发生DRT的时间更短( 。DAPT风险比(HR) = 0.334, = 0.015,95%CI:0.131 - 0.850)。服用利伐沙班10 mg组DRT的中位数长度显著低于DAPT组(1.721[1.610 - 1.818]mm 1.820[1.725 - 1.925]mm, = 0.029)。与具有相似充血性心力衰竭、高血压、年龄≥75岁、糖尿病、既往卒中或短暂性脑缺血发作或血栓栓塞、血管疾病、年龄65 - 74岁、性别类别( - )评分的患者未经调整的缺血事件估计发生率相比,服用利伐沙班10 mg组缺血性卒中发生率显著降低68.6%,这使得总体血栓栓塞事件减少了54.9%。三组总体轻微出血情况无显著差异( = 0.944)。与服用利伐沙班15 mg组和服用利伐沙班10 mg组相比,DAPT组手术相关出血更常见。
封堵植入成功后,与DAPT相比,长期RRD显著降低了DRT和TE的发生。